Dongxia Wang

机构：Hebei Medical University, Shanxi Medical University, Dalian Medical University, Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, Shenzhen Technology University, Shanxi Provincial People’s Hospital, Shanxi Cardiovascular Hospital · ORCID：0000-0003-3361-8045

发表论文 85 篇 · 总被引 932 次 · h-index 19

代表论文

• Nox4 as a novel therapeutic target for diabetic vascular complications (2023 · Redox Biology · 被引 92)
• Recent Advances in Microfluidic Chip Technology for Laboratory Medicine: Innovations and Artificial Intelligence Integration (2026 · Biosensors · 被引 18)
• Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis (2023 · BMC Cancer · 被引 15)
• Ferroptosis patterns and tumor microenvironment infiltration characterization in esophageal squamous cell cancer (2022 · Frontiers in Genetics · 被引 11)
• Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304) (2025 · Cancer Research · 被引 7)
• Vitamin D and Atherosclerosis: Unraveling the Impact on Macrophage Function (2024 · Molecular Nutrition & Food Research · 被引 7)